Penumbra Q2 FY26 net income falls to 34.81 million; revenue rises 14.9% to 390 million

Reuters2026/07/30 20:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Penumbra reported Q2 revenue of USD 390 million, up 14.9% from a year earlier, led by embolization and access at USD 131.1 million, up 20%.
Thrombectomy revenue rose 12.5% to USD 259 million.
Operating income was USD 41 million; net income fell to USD 34.8 million, or USD 0.88 a share.
Gross margin widened 1.9 percentage points to 67.9%, while operating expenses climbed to USD 223.9 million, including USD 6.9 million in acquisition-related costs.
Penumbra withdrew full-year 2026 guidance and will not hold an earnings call due to its pending acquisition by Boston Scientific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607301605PR_NEWS_USPR_____SF15117) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Penumbra Q2 FY26 net income falls to 34.81 million; revenue rises 14.9% to 390 million

You may also like

Crypto prices